JP2016515123A5 - - Google Patents

Download PDF

Info

Publication number
JP2016515123A5
JP2016515123A5 JP2016502230A JP2016502230A JP2016515123A5 JP 2016515123 A5 JP2016515123 A5 JP 2016515123A5 JP 2016502230 A JP2016502230 A JP 2016502230A JP 2016502230 A JP2016502230 A JP 2016502230A JP 2016515123 A5 JP2016515123 A5 JP 2016515123A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
amino acid
composition according
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515123A (ja
JP6434485B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026736 external-priority patent/WO2014151962A1/en
Publication of JP2016515123A publication Critical patent/JP2016515123A/ja
Publication of JP2016515123A5 publication Critical patent/JP2016515123A5/ja
Application granted granted Critical
Publication of JP6434485B2 publication Critical patent/JP6434485B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502230A 2013-03-15 2014-03-13 Pla2g12aポリペプチド及びpla2g12a変異ポリペプチドを使用して代謝障害を治療する方法 Active JP6434485B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793503P 2013-03-15 2013-03-15
US61/793,503 2013-03-15
PCT/US2014/026736 WO2014151962A1 (en) 2013-03-15 2014-03-13 Method of treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides

Publications (3)

Publication Number Publication Date
JP2016515123A JP2016515123A (ja) 2016-05-26
JP2016515123A5 true JP2016515123A5 (https=) 2017-03-23
JP6434485B2 JP6434485B2 (ja) 2018-12-05

Family

ID=50483573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502230A Active JP6434485B2 (ja) 2013-03-15 2014-03-13 Pla2g12aポリペプチド及びpla2g12a変異ポリペプチドを使用して代謝障害を治療する方法

Country Status (6)

Country Link
US (1) US9474792B2 (https=)
EP (1) EP2968480B1 (https=)
JP (1) JP6434485B2 (https=)
AU (1) AU2014236728B2 (https=)
CA (1) CA2906540C (https=)
WO (1) WO2014151962A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151962A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Method of treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides
BR112017004056A2 (pt) 2014-09-12 2017-12-05 Biogen Ma Inc composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
EP3263600A1 (en) 2016-07-01 2018-01-03 Université Claude Bernard Lyon 1 Inhibition of pla2r1 for the prevention and/or the treatment of type 2-diabetes
US20220211821A1 (en) * 2019-05-08 2022-07-07 University-Inoustry Cooperation Group Of Kyung Hee University Composition for preventing or treating obesity, comprising phospholipase a2 as active ingredient
CR20220485A (es) * 2020-02-28 2022-11-10 Ionis Pharmaceuticals Inc Compuestos y métodos para modular smn2
EP4504052A4 (en) * 2022-04-01 2026-04-01 Massachusetts Gen Hospital VECTORS AND METHODS FOR THE TREATMENT OF NEURODEGENERESCENCE, DELAYING COGNITIVE DECLINE AND IMPROVING MEMORY

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
AU774986B2 (en) * 1998-12-24 2004-07-15 Sylus Pharmaceuticals Ltd Glycosyl phosphatidy linositol specific phospholipase D proteins and uses thereof
US20140099295A1 (en) * 2011-05-02 2014-04-10 Ngm Biopharmaceuticals, Inc. Methods of Treating Glucose Metabolism Disorders
WO2012151159A1 (en) * 2011-05-02 2012-11-08 Ngm Biopharmaceuticals, Inc. Methods of modulating pla2g12a levels and treating disorders associated therewith
WO2014151962A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Method of treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides

Similar Documents

Publication Publication Date Title
JP2014511863A5 (https=)
JP2016515123A5 (https=)
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
JP2016509011A5 (https=)
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
WO2017009236A3 (en) New exendin-4 derivatives as selective peptidic dual glp-1 / glucagon receptor agonists
NZ726623A (en) Improved peptide pharmaceuticals for insulin resistance
JP2015517488A5 (https=)
JP2015518818A5 (https=)
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
JP2016222689A5 (ja) 合成ペプチド及び乾燥粉末薬剤輸送システム
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
JP2016532690A5 (https=)
JP2014530220A5 (https=)
JP2012041342A5 (https=)
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
MX386595B (es) Métodos para el tratamiento del sobrepeso o la obesidad.
JP2015110588A5 (https=)
MX2019008949A (es) Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
WO2011112867A8 (en) The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
EA201691789A1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов